PMID- 28708873
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20180122
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 7
DP  - 2017
TI  - Impact of early cART on HIV blood and semen compartments at the time of primary
      infection.
PG  - e0180191
LID - 10.1371/journal.pone.0180191 [doi]
AB  - BACKGROUND: HIV-infected cells in semen facilitate viral transmission. We studied
      the establishment of HIV reservoirs in semen and blood during PHI, along with
      systemic immune activation and the impact of early cART. METHODS: Patients in the
      ANRS-147-OPTIPRIM trial received two years of early cART. Nineteen patients of
      the trial were analyzed, out of which 8 had acute PHI (WB </=1 Ab). We quantified
      total cell-associated (ca) HIV-DNA in blood and semen and HIV-RNA in blood and
      semen plasma samples, collected during PHI and at 24 months of treatment.
      RESULTS: At enrollment, HIV-RNA load was higher in blood than in semen (median
      5.66 vs 4.22 log10 cp/mL, p<0.0001). Semen HIV-RNA load correlated strongly with 
      blood HIV-RNA load (r = 0.81, p = 0.02, the CD4 cell count (r = -0.98, p<0.0001),
      and the CD4/CD8 ratio (r = -0.85, p<0.01) in acute infection but not in later
      stages of PHI. Median blood and seminal cellular HIV-DNA levels were 3.59 and
      0.31 log10cp/106 cells, respectively. HIV-DNA load peaked in semen later than in 
      blood and then correlated with blood IP10 level (r = 0.62, p = 0.04). HIV-RNA was
      undetectable in blood and semen after two years of effective cART. Semen HIV-DNA 
      load declined similarly, except in one patient who had persistently high IP-10
      and IL-6 levels and used recreational drugs. CONCLUSIONS: HIV reservoir cells are
      found in semen during PHI, with gradual compartmentalization. Its size was linked
      to the plasma IP-10 level. Early treatment purges both the virus and infected
      cells, reducing the high risk of transmission during PHI. CLINICAL TRIALS
      REGISTRATION: NCT01033760.
FAU - Cheret, Antoine
AU  - Cheret A
AUID- ORCID: http://orcid.org/0000-0001-7295-3132
AD  - Internal Medicine Unit, Bicetre Hospital, APHP, Le Kremlin-Bicetre, France.
AD  - EA 7327 Paris Descartes University, Paris, France.
FAU - Durier, Christine
AU  - Durier C
AUID- ORCID: http://orcid.org/0000-0002-9825-2921
AD  - INSERM SC10-US19, Villejuif, France.
FAU - Melard, Adeline
AU  - Melard A
AD  - EA 7327 Paris Descartes University, Paris, France.
AD  - Virology Laboratory, CHU Necker, APHP, Paris, France.
FAU - Ploquin, Mickael
AU  - Ploquin M
AD  - Institute Pasteur, HIV, Inflammation and Persistence Unit, Paris, France.
FAU - Heitzmann, Julia
AU  - Heitzmann J
AUID- ORCID: http://orcid.org/0000-0002-2587-2580
AD  - INSERM SC10-US19, Villejuif, France.
FAU - Lecuroux, Camille
AU  - Lecuroux C
AD  - INSERM U 1184, Paris Sud University, Bicetre Hospital, APHP, Le Kremlin Bicetre, 
      France.
FAU - Avettand-Fenoel, Veronique
AU  - Avettand-Fenoel V
AD  - EA 7327 Paris Descartes University, Paris, France.
AD  - Virology Laboratory, CHU Necker, APHP, Paris, France.
FAU - David, Ludivine
AU  - David L
AD  - EA 7327 Paris Descartes University, Paris, France.
FAU - Pialoux, Gilles
AU  - Pialoux G
AD  - Infectious Diseases Department, Tenon Hospital, APHP, Paris, France.
FAU - Chennebault, Jean-Marie
AU  - Chennebault JM
AD  - Infectious Diseases Department, Angers Hospital, Angers, France.
FAU - Muller-Trutwin, Michaela
AU  - Muller-Trutwin M
AUID- ORCID: http://orcid.org/0000-0002-3854-2396
AD  - Institute Pasteur, HIV, Inflammation and Persistence Unit, Paris, France.
FAU - Goujard, Cecile
AU  - Goujard C
AUID- ORCID: http://orcid.org/0000-0002-7956-0822
AD  - Internal Medicine Unit, Bicetre Hospital, APHP, Le Kremlin-Bicetre, France.
FAU - Rouzioux, Christine
AU  - Rouzioux C
AD  - EA 7327 Paris Descartes University, Paris, France.
AD  - Virology Laboratory, CHU Necker, APHP, Paris, France.
FAU - Meyer, Laurence
AU  - Meyer L
AD  - INSERM SC10-US19, Villejuif, France.
AD  - INSERM, CESP U1018, Universite Paris Sud, Universite Paris Saclay, Faculte de
      Medecine Paris-Sud, Service d'Epidemiologie et de Sante Publique, AP-HP, Hopital 
      Bicetre, Le Kremlin-Bicetre, France.
CN  - ANRS OPTIPRIM study group
LA  - eng
SI  - ClinicalTrials.gov/NCT01033760
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170714
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - CD4-CD8 Ratio
MH  - Enzyme-Linked Immunosorbent Assay
MH  - HIV Infections/*drug therapy
MH  - HIV-1/genetics/isolation & purification
MH  - Humans
MH  - Interleukin-6/analysis
MH  - Leukocytes, Mononuclear/virology
MH  - Male
MH  - Middle Aged
MH  - Principal Component Analysis
MH  - RNA, Viral/analysis/*blood
MH  - Real-Time Polymerase Chain Reaction
MH  - Semen/*virology
MH  - Time Factors
MH  - Viral Load
MH  - Young Adult
PMC - PMC5510829
EDAT- 2017/07/15 06:00
MHDA- 2017/09/28 06:00
CRDT- 2017/07/15 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/06/12 00:00 [accepted]
PHST- 2017/07/15 06:00 [entrez]
PHST- 2017/07/15 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
AID - 10.1371/journal.pone.0180191 [doi]
AID - PONE-D-17-14604 [pii]
PST - epublish
SO  - PLoS One. 2017 Jul 14;12(7):e0180191. doi: 10.1371/journal.pone.0180191.
      eCollection 2017.